
    
      E-SERIES Registry is Prospective, multinational (Asia, South America and Europe),
      non-randomized, post-marketing web-based registry.

      For this Study Up to 100 clinical sites in Asia, South America and Europe. Patients "ALL
      COMERS" assigned for percutaneous coronary interventions who present with at least one
      angiographically documented coronary artery lesion suitable for percutaneous treatment with
      the Supralimus® SES.

      All subjects who provided signed informed consent prior to procedure, and have at least one
      lesion in a major epicardial vessel or major branch (>2.25mm), and are suitable for
      percutaneous treatment including stenting procedure with the Supralimus® SES. There are no
      limit regarding the number of lesions and/or study stents to be used, and stenting technique
      will be left at the operator's discretion; however, it is recommended according to the BEST
      interventional practice according to the current guidelines.

      All patients will undergo follow-up clinical evaluation at 1, 6, 12 and 24 months.
      Angiographic follow-up will be performed at 6 months in a subset of high risk lesions
      including bifurcations (first 100 lesions) and left main stem (first 100 lesions).
    
  